Charissa Liu
E-mail：sales05@staherb.cn? ? sales@staherb.cn
Whatsapp:+86-13657431735
Wechat:+86-13657431735
一、核心藥理機(jī)制（Core Pharmacological Mechanisms）
中文簡(jiǎn)介：
大黃酚的藥理核心在于干預(yù)細(xì)胞信號(hào)轉(zhuǎn)導(dǎo)、調(diào)控氧化還原穩(wěn)態(tài)及影響代謝通路，具體機(jī)制如下：
抗腫瘤與增殖抑制（Antitumor & Anti-proliferation）：抑制EGF誘導(dǎo)的EGFR酪氨酸磷酸化（Tyr1068），阻斷下游AKT、ERK、mTOR/p70S6K通路激活，劑量依賴性抑制EGFR過(guò)表達(dá)的人結(jié)腸癌細(xì)胞（SNU-C5）增殖；誘導(dǎo)腫瘤細(xì)胞凋亡與周期阻滯，并具潛在逆轉(zhuǎn)多藥耐藥潛力。
神經(jīng)保護(hù)與抗氧化（Neuroprotection & Antioxidant）：抑制BV2小膠質(zhì)細(xì)胞活化，下調(diào)TNF-α、IL-1β、IL-6等促炎因子；激活Nrf2/HO-1抗氧化防御系統(tǒng)，提升SOD、GSH水平，減少ROS介導(dǎo)的DNA氧化；抑制Drp1介導(dǎo)的線粒體分裂及NF-κB/P50/P65通路，減輕腦缺血再灌注（I/R）損傷、阿爾茨海默病及帕金森病模型中的神經(jīng)元損傷。
抗炎與臟器保護(hù)（Anti-inflammatory & Organ Protection）：抑制NF-κB、MAPK（p38/ERK）、JAK-STAT信號(hào)軸及NLRP3炎癥小體組裝（下調(diào)caspase-1、IL-1β），減輕類風(fēng)濕性關(guān)節(jié)炎、結(jié)腸炎及急性腎損傷（AKI）；通過(guò)激活PI3K/Akt通路改善線粒體膜電位與自噬，拮抗阿霉素（DOX）誘導(dǎo)的心肌毒性（抑制PARP1過(guò)度活化）。
代謝調(diào)節(jié)與抗肥胖（Metabolic Regulation & Anti-obesity）：通過(guò)激活AMPK通路，下調(diào)3T3-L1脂肪細(xì)胞中脂肪生成因子，抑制脂質(zhì)積累并誘導(dǎo)產(chǎn)熱；在HFD誘導(dǎo)的肥胖小鼠模型中顯著減輕體重增加與代謝紊亂。
抗菌、止咳與生理調(diào)節(jié)（Antimicrobial, Antitussive & Physiological）：對(duì)甲型鏈球菌、肺炎球菌、流感桿菌、卡他球菌及皮膚癬菌等有抑制作用；具較明顯的止咳作用；能促進(jìn)腸管運(yùn)動(dòng)（潛在瀉下）、縮短凝血時(shí)間及利尿（大鼠模型）。
English Introduction:
The core pharmacology of Chrysophanol (Chrysophanic acid) lies in interfering with cellular signaling, modulating redox homeostasis, and regulating metabolic pathways:
Antitumor & Anti-proliferation: Inhibits EGF-induced EGFR tyrosine phosphorylation (Tyr1068) and blocks downstream AKT, ERK, mTOR/p70S6K activation, dose-dependently suppressing proliferation of EGFR-overexpressing human colon cancer cells (SNU-C5); induces tumor cell apoptosis/cycle arrest and potential multidrug resistance reversal.
Neuroprotection & Antioxidant: Suppresses BV2 microglial activation, downregulating TNF-α, IL-1β, IL-6; activates Nrf2/HO-1 antioxidant defense to elevate SOD/GSH and reduce ROS-mediated DNA oxidation; inhibits Drp1-mediated mitochondrial fission and NF-κB/P50/P65 to alleviate neuronal damage in cerebral I/R injury, AD, and PD models.
Anti-inflammatory & Organ Protection: Suppresses NF-κB, MAPK (p38/ERK), JAK-STAT axes and NLRP3 inflammasome assembly (downregulating caspase-1, IL-1β), mitigating rheumatoid arthritis, colitis, and acute kidney injury (AKI); activates PI3K/Akt to improve mitochondrial membrane potential/autophagy and antagonizes DOX-induced cardiotoxicity (inhibiting PARP1 overactivation).
Metabolic Regulation & Anti-obesity: Activates AMPK pathway, downregulates adipogenic factors in 3T3-L1 adipocytes, inhibits lipid accumulation and induces thermogenesis; significantly reduces weight gain and metabolic disorders in HFD-induced obese mice.
Antimicrobial, Antitussive & Physiological: Inhibits S. pyogenes, S. pneumoniae, H. influenzae, Branhamella catarrhalisand dermatophytes; exhibits significant antitussive effect; promotes intestinal motility (potential catharsis), shortens blood coagulation time, and diuretic effect (rat model).
二、核心功效分類（Core Efficacy Categories）
1. 抗腫瘤與研究級(jí)藥效（Antitumor & Research-grade Efficacy）
中文：體外對(duì)結(jié)腸癌（SNU-C5）、黑色素瘤等有增殖抑制；通過(guò)EGFR/mTOR阻斷與凋亡誘導(dǎo)作天然抗腫瘤先導(dǎo)化合物研究，非臨床治療；與大分子藥物聯(lián)用具協(xié)同潛力。
English: In vitro inhibition of colon cancer (SNU-C5), melanoma etc.; serves as natural antitumor lead compound via EGFR/mTOR blockade & apoptosis induction for R&D, not clinical therapy; synergistic potential with other agents.
2. 神經(jīng)保護(hù)與心腦血管/臟器修復(fù)（Neuroprotection & Cardio-renal Protection）
中文：研究級(jí)顯示減輕腦缺血再灌注、阿爾茨海默/帕金森氧化應(yīng)激、阿霉素心肌毒性、急性腎損傷；抑制NLRP3/NF-κB與PARP1，具神經(jīng)、心肌、腎臟背景保護(hù)，多作動(dòng)物模型工具藥。
English: Research-grade mitigation of cerebral I/R, AD/PD oxidative stress, DOX cardiotoxicity, AKI; inhibits NLRP3/NF-κB & PARP1 for neuro-, cardio-, renal protective background, mostly as animal model tool compounds.
3. 抗炎、代謝與腸道調(diào)節(jié)（Anti-inflammatory, Metabolic & Intestinal Modulation）
中文：調(diào)控Nrf2/NF-κB/JAK-STAT改善類風(fēng)濕性關(guān)節(jié)炎、結(jié)腸炎；激活A(yù)MPK抗肥胖與脂質(zhì)積累；促進(jìn)腸管運(yùn)動(dòng)（傳統(tǒng)瀉下成分背景），具抗炎、代謝調(diào)節(jié)與生理蠕動(dòng)研究?jī)r(jià)值。
English: Modulates Nrf2/NF-κB/JAK-STAT to ameliorate RA, colitis; activates AMPK against obesity/lipid accumulation; promotes intestinal motility (traditional cathartic context), valuable for anti-inflammatory, metabolic & physiological motility research.
4. 抗菌、止咳與植物源應(yīng)用（Antimicrobial, Antitussive & Botanical Application）
中文：抑制呼吸道球菌與皮膚癬菌，具止咳作用；作植物源抗真菌（皮膚癬/地衣防御素功能）研究及分析對(duì)照品（大黃/何首烏/決明子質(zhì)控）。
English: Inhibits respiratory cocci & dermatophytes with antitussive effect; used in botanical antifungal (dermatophyte/lichen defense) research and analytical reference (QC for Rhubarb/Fo-Ti/Cassia).
?? 關(guān)鍵特性與合規(guī)提示（Critical Notes & Regulatory）
中文：
非內(nèi)服原料：屬蒽醌衍生物，具潛在瀉下、肝腎代謝負(fù)擔(dān)、光毒與細(xì)胞毒性，高純單體僅限科研/外用/農(nóng)用，嚴(yán)禁作為普通食品、保健品、內(nèi)服OTC原料；
光敏與穩(wěn)定性：蒽醌母核在強(qiáng)紫外、堿、高溫下易氧化變色/開環(huán)，儲(chǔ)運(yùn)須2~8℃或-20℃充氮避光；
研究局限：多數(shù)功效基于體外細(xì)胞或動(dòng)物模型，生物利用度受水溶性差限制，不作人體療效宣稱；
農(nóng)用/外用合規(guī)：作農(nóng)藥/日化須符合相應(yīng)法規(guī)與刺激評(píng)估，避免高濃度接觸黏膜與破損皮膚。
English:
Not for Internal Use: An anthraquinone derivative with potential cathartic effect, hepatic/renal burden, phototoxicity & cytotoxicity; high-pure monomer is exclusively for R&D/topical/agricultural use, strictly NOT for food/supplement/oral OTC APIs;
Photosensitivity & Stability: Anthraquinone core sensitive to UV, alkali, high heat (oxidation/discoloration/ring-opening); store 2~8℃ or -20℃ N? light-proof;
Research Limitation: Most effects are in vitro/in animal models with limited bioavailability due to poor water solubility; no human therapeutic claims;
Agri/Cosmetic Compliance: Requires regulatory compliance & irritation assessment if used in pesticides/cosmetics; avoid high-conc contact with mucosa/broken skin.
公司官網(wǎng) http://www.staherb.com/ 資質(zhì):HALAL, KOSHER等認(rèn)證
?：19573130018 楊經(jīng)理（微信同號(hào)）